Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Yamaki, Tomohiro ^a,b   Suenaga, Yusuke ^a   Iuchi, Toshihiko ^a   Alagu, Jennifer ^a   Takatori, Atsushi ^a   Itami, Makiko ^a   Araki, Akinobu ^a   Ohira, Miki ^a   Inoue, Masahiro ^c   Kageyama, Hajime ^a   Yokoi, Sana ^a   Saeki, Naokatsu ^b   Nakagawara, Akira ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; MYC PROTEIN; TEMOZOLOMIDE; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL PROLIFERATION; DRUG EFFECT; GLIOBLASTOMA; HUMAN; METABOLISM; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL PROLIFERATION; DACARBAZINE; GLIOBLASTOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

MLCS; MLOWN;

EID: 84879969390     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01160     Document Type: Article

References (33)

1. Chen, J., McKay, R. M. & Parada, L. F. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 149, 36-47 (2012).
2. Mrugala, M. M. & Chamberlain, M. C. Mechanisms of disease: temozolomide and glioblastoma - look to the future. Nat. Clin. Pract. Oncol. 5, 476-486 (2008).
3. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
4. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
5. Shah, N. et al. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One 6, e16146 (2011).
6. Beier, D., Schulz, J. B. & Beier, C. P. Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Mol. Cancer 10, 128 (2011).
7. Osada, M. et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4, 839-843 (1998).
8. Yang, A. et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2, 305-316 (1998).
9. Kaghad, M. et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819 (1997).
10. Stiewe, T. The p53 family in differentiation and tumorigenesis. Nat. Rev. Cancer 7, 165-168 (2007).
11. Deyoung, M. P. & Ellisen, L. W. p63 and p73 in human cancer: defining the network. Oncogene 26, 5169-5183 (2007).
12. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
13. Suenaga, Y. et al. TATA-binding protein (TBP)-like protein is engaged in etoposide-induced apoptosis through transcriptional activation of human TAp63 gene. J. Biol. Chem. 284, 35433-35440 (2009).
14. Aguda, B. D., Kim, Y., Kim, H. S., Friedman, A. & Fine, H. A. Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation. Biophys. J. 101, 2082-2091 (2011).
15. Bredel, M. et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 65, 8679-8689 (2005).
16. Zheng, H. et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455, 1129-1133 (2008).
17. Ho, J. S., Ma, W., Mao, D. Y. & Benchimol, S. p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell Biol. 25, 7423-7431 (2005).
18. Krieg, A. J., Hammond, E. M. & Giaccia, A. J. Functional analysis of p53 binding under differential stresses. Mol. Cell Biol. 26, 7030-7045 (2006).
19. Kondo, J. et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. USA 108, 6235-6240 (2011).
20. Wang, J. et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One 3, e3769 (2008).
21. Su, X. et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467, 986-990 (2010).
22. Melino, G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 18, 1487-1499 (2011).
23. Kim, S., Han, J., Kim, J. & Park, C. Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res. 64, 6900-6905 (2004).
24. Adorno, M. et al. A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 137, 87-98 (2009).
25. Sachdeva, M. et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA 106, 3207-3212 (2009).
26. Guo, X. et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat. Cell Biol. 11, 1451-1457 (2009).
27. Janouskova, H. et al. Integrin α5b1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res. 72, 3463-3470 (2012).
28. Zhang, W. B. et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem. 285, 40461-40471 (2010).
29. Blough, M. D. et al. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J. Neurooncol. 102, 1-7 (2011).
30. Dinca, E. B. et al. p53 small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res. 68, 10034-10039 (2008).
31. Weller, M. et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol. 27, 5743-5750 (2009).
32. Iuchi, T. et al. Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int. J. Radiat. Oncol. Biol. Phys. 64, 1317-1324 (2006).
33. Ohira, M. et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7, 337-350 (2005).